| Small-molecule inhibitors of the programmed cell death-1/programmed death-ligand 1 (PD-1/PD-L1) interaction via transiently induced protein states and dimerization of PD-L1 K Guzik, KM Zak, P Grudnik, K Magiera, B Musielak, R Torner, L Skalniak, ... Journal of Medicinal Chemistry 60 (13), 5857-5867, 2017 | 290 | 2017 |
| Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells L Skalniak, KM Zak, K Guzik, K Magiera, B Musielak, M Pachota, ... Oncotarget 8 (42), 72167, 2017 | 256 | 2017 |
| Conserved conformational changes in the ATPase cycle of human Hsp90 K Richter, J Soroka, L Skalniak, A Leskovar, M Hessling, J Reinstein, ... Journal of Biological Chemistry 283 (26), 17757-17765, 2008 | 171 | 2008 |
| Bioactive macrocyclic inhibitors of the PD‐1/PD‐L1 immune checkpoint K Magiera‐Mularz, L Skalniak, KM Zak, B Musielak, E Rudzinska‐Szostak, ... Angewandte Chemie International Edition 56 (44), 13732-13735, 2017 | 162 | 2017 |
| CA-170–a potent small-molecule PD-L1 inhibitor or not? B Musielak, J Kocik, L Skalniak, K Magiera-Mularz, D Sala, M Czub, ... Molecules 24 (15), 2804, 2019 | 123 | 2019 |
| Regulatory feedback loop between NF‐κB and MCP‐1‐induced protein 1 RNase L Skalniak, D Mizgalska, A Zarebski, P Wyrzykowska, A Koj, J Jura The FEBS journal 276 (20), 5892-5905, 2009 | 120 | 2009 |
| Monocyte chemotactic protein-1-induced protein-1 (MCPIP1) is a novel multifunctional modulator of inflammatory reactions J Jura, L Skalniak, A Koj Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 1823 (10), 1905-1913, 2012 | 104 | 2012 |
| Effects triggered by platinum nanoparticles on primary keratinocytes P Konieczny, AG Goralczyk, R Szmyd, L Skalniak, J Koziel, FL Filon, ... International Journal of Nanomedicine, 3963-3975, 2013 | 85 | 2013 |
| Design, Synthesis, Evaluation, and Structural Studies of C2-Symmetric Small Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 … S Basu, J Yang, B Xu, K Magiera-Mularz, L Skalniak, B Musielak, ... Journal of medicinal chemistry 62 (15), 7250-7263, 2019 | 81 | 2019 |
| Effect of silver nanoparticles on human primary keratinocytes R Szmyd, AG Goralczyk, L Skalniak, A Cierniak, B Lipert, FL Filon, ... Biological Chemistry 394 (1), 113-123, 2013 | 63 | 2013 |
| Di-bromo-based small-molecule inhibitors of the PD-1/PD-L1 immune checkpoint M Konieczny, B Musielak, J Kocik, L Skalniak, D Sala, M Czub, ... Journal of Medicinal Chemistry 63 (19), 11271-11285, 2020 | 55 | 2020 |
| Prolonged idasanutlin (RG7388) treatment leads to the generation of p53-mutated cells L Skalniak, J Kocik, J Polak, A Skalniak, M Rak, A Wolnicka-Glubisz, ... Cancers 10 (11), 396, 2018 | 54 | 2018 |
| Lithocholic acid hydroxyamide destabilizes cyclin D1 and induces G0/G1 arrest by inhibiting deubiquitinase USP2a K Magiera, M Tomala, K Kubica, V De Cesare, M Trost, BJ Zieba, ... Cell chemical biology 24 (4), 458-470. e18, 2017 | 49 | 2017 |
| Terphenyl-based small-molecule inhibitors of programmed cell death-1/programmed death-ligand 1 protein–protein interaction D Muszak, E Surmiak, J Plewka, K Magiera-Mularz, J Kocik-Krol, ... Journal of medicinal chemistry 64 (15), 11614-11636, 2021 | 48 | 2021 |
| Human and mouse PD-L1: similar molecular structure, but different druggability profiles K Magiera-Mularz, J Kocik, B Musielak, J Plewka, D Sala, M Machula, ... Iscience 24 (1), 2021 | 48 | 2021 |
| A therapeutic patent overview of MDM2/X-targeted therapies (2014–2018) L Skalniak, E Surmiak, TA Holak Expert Opinion on Therapeutic Patents 29 (3), 151-170, 2019 | 38 | 2019 |
| Multicomponent peptide stapling as a diversity‐driven tool for the development of inhibitors of protein–protein interactions MG Ricardo, AM Ali, J Plewka, E Surmiak, B Labuzek, CG Neochoritis, ... Angewandte Chemie International Edition 59 (13), 5235-5241, 2020 | 35 | 2020 |
| Helping the released guardian: drug combinations for supporting the anticancer activity of HDM2 (MDM2) antagonists J Kocik, M Machula, A Wisniewska, E Surmiak, TA Holak, L Skalniak Cancers 11 (7), 1014, 2019 | 35 | 2019 |
| 1, 4, 5-trisubstituted imidazole-based p53–MDM2/MDMX antagonists with aliphatic linkers for conjugation with biological carriers A Twarda-Clapa, S Krzanik, K Kubica, K Guzik, B Labuzek, ... Journal of medicinal chemistry 60 (10), 4234-4244, 2017 | 30 | 2017 |
| Proteasome inhibitor MG‐132 induces MCPIP 1 expression L Skalniak, A Koj, J Jura The FEBS journal 280 (11), 2665-2674, 2013 | 30 | 2013 |
